Immuron Limited — FY2020 Form 20-F
Reporting period: Fiscal year ended June 30, 2020; financial statements are in Australian dollars (A$) and prepared under IFRS. The filing is an annual report, not a 2019 Q4 report. Immuron sells Travelan and Protectyn and is developing oral antibody treatments for infectious diseases.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | A$2.519 million | A$2.387 million |
| Gross profit | A$1.830 million | A$1.720 million |
| Gross margin | About 73% | About 72% |
| Operating loss | A$2.906 million | A$4.656 million |
| Net loss | A$2.927 million | A$4.656 million |
| Operating cash flow | Used A$3.147 million | Used A$1.799 million |
| Cash and cash equivalents at year-end | A$3.250 million | A$5.120 million |
| Total assets | A$6.202 million | A$8.562 million |
| Total liabilities | A$0.558 million | A$1.211 million |
Revenue rose 5%, while gross profit increased 6%. The lower net loss mainly reflected a reduction in general and administrative expenses, including a substantial negative share-based payment expense in FY2020 following option revaluation and forfeitures. Research and development costs increased 13% to A$1.179 million. Operating cash outflow worsened as payments to suppliers increased and R&D tax-incentive receipts declined. Current assets were A$4.409 million versus current liabilities of A$0.516 million. The company reported no credit facilities; year-end lease liabilities were A$61,105.
Material changes and business developments
- COVID-19 travel restrictions sharply reduced Travelan sales from March 2020 and weakened fourth-quarter sales. Management said earlier FY2020 sales had grown about 60% in the first three quarters; full-year gross Travelan sales were A$2.7 million.
- Immuron cut costs and temporarily suspended capital-intensive clinical work on IMM-124E and IMM-529, while reprioritizing resources toward IMM-529 for recurrent C. difficile. A planned Phase III travelers’ diarrhea program for IMM-124E was postponed.
- The company continued a U.S. Department of Defense-supported program for a Campylobacter/ETEC product. It reported a planned 2021 start for two controlled human infection-model trials, subject to development progress and approvals.
- Immuron reported preliminary laboratory neutralization results for SARS-CoV-2 using IMM-124E-related product lots and said it filed a provisional patent application. These were in-vitro findings, not evidence of clinical efficacy.
- On July 24, 2020, after fiscal year-end, Immuron raised equity through an ADS offering. The filing describes gross proceeds as US$20 million in one section and US$18.38 million in the financial-statement note, a discrepancy requiring verification. It states direct offering costs of US$1.6 million and an additional A$1.6 million discretionary KMP amount expensed after year-end. Management said the financing supported at least 12 months of operations and development.
Outlook, risks and unusual items
- Management expects continued operating losses and says additional funding will be needed to meet longer-term objectives. Future funding, clinical costs, regulatory outcomes, collaborations and product sales are uncertain.
- COVID-19 effects on sales and clinical development remained uncertain. Travel restrictions directly affected the principal commercial product, while clinical studies and recruitment faced disruption.
- Prescription candidates have not generated sales and remain subject to clinical, regulatory, manufacturing, market-acceptance and financing risks. IMM-124E did not demonstrate clinical benefit on the primary liver-fat endpoint in a NASH Phase II study; separate alcoholic-hepatitis and pediatric NAFLD studies also did not support continued development for those indications.
- Immuron relies on third parties for trials and manufacturing, including a sole manufacturer for its lead compound, and had not secured commercial-scale manufacturing capacity for prescription candidates.
- The company recognized A$308,225 of estimated Australian R&D tax-incentive income and A$154,904 of COVID-related grants. Eligibility and future availability of the incentive are risks.
- Management identified material weaknesses in financial reporting controls and concluded disclosure controls and internal control over financial reporting were ineffective at June 30, 2020. Prior periods were revised for errors management characterized as immaterial, including accounting for representative warrants and shares issued for related-party services. The auditor gave an unqualified opinion on the IFRS financial statements but did not opine on internal controls.
- No contingent liabilities were reported at June 30, 2020. No dividends are anticipated in the foreseeable future.
Most important facts for investors to verify
- Reconcile the July 2020 offering proceeds: US$20 million versus US$18.38 million disclosed in different parts of the filing, and confirm net proceeds and the post-year-end KMP expense.
- Track post-financing cash use, operating cash burn, and the timing and terms of any further funding.
- Check whether COVID-related sales weakness persisted and whether Travelan demand recovered as travel resumed.
- Confirm whether the planned Campylobacter/ETEC trials and IMM-529 development advanced, and distinguish preclinical or laboratory findings from clinical evidence.
- Monitor remediation of the disclosed material weaknesses and any further restatements or control findings.
- Assess inventory recoverability and use: A$1.722 million of raw-material inventory was classified as non-current and expected to be consumed beyond 12 months.